Author(s)

Raiza Ruiz-Lorente¹, Sayly Alfonso², Eduardo Santiesteban³, Yamilka Sánchez⁴, Kirenia Camacho⁵, Erasmo Mendoza⁵, Carmen Elena Viada⁶, Ramón Ortiz², Ihosvannys Carreño⁵, Mayelin Troche⁶, Meylan Cepeda⁶, Ana Rosa Vals⁶, Leticia Cabrera⁶, Annia Gorte⁶, Delmis Batista⁶, Milagros Domenech⁶, Yanela Santiesteban⁶, Yuliannis Santiesteban⁶, Daymys Estevez⁶, Jessica García-Viamontes¹, Conrado Ramos Mico¹, Mayra Ramos-Suzarte^6*

¹González Coro Hospital, La Habana, Cuba.
²Celestino Hernández Robau Hospital, Villa Clara, Cuba.
³Jose Ramón Lopez Tabranes Hospital, Matanzas, Cuba.
⁴III Congreso Hospital, Pinar del Río, Cuba.
⁵Faustino Perez Hospital, Matanzas, Cuba.
⁶Center of Molecular Immunology, Havana, Cuba.

Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF^®, the humanized mAb nimotuzumab or the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with a more than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9%; 1.1% and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for CIMAvax-EGF^®, nimotuzumab and the combination of both, respectively. Thus fulfilling the hypothesis of safety and efficacy proposed in the investigation was achieved. The three therapeutic regimens achieved overall survival rates greater than 35% at 60 months, encouraging results for advanced uterine cervical cancer. A phase III clinical trial is proposed to consolidate these results in a greater number of patients with nimotuzumab as study drug.

CIMAvax-EGF^®, Nimotuzumab, Survival, Safety, Advanced Cervical Cancer

Ruiz-Lorente, R. , Alfonso, S. , Santiesteban, E. , Sánchez, Y. , Camacho, K. , Mendoza, E. , Viada, C. , Ortiz, R. , Carreño, I. , Troche, M. , Cepeda, M. , Vals, A. , Cabrera, L. , Gorte, A. , Batista, D. , Domenech, M. , Santiesteban, Y. , Santiesteban, Y. , Estevez, D. , García-Viamontes, J. , Mico, C. and Ramos-Suzarte, M. (2021) Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF^® Therapeutic Vaccine. Journal of Cancer Therapy, 12, 146-156. doi: 10.4236/jct.2021.123016.